REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

13 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

17 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2024 Results

13 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

14 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences in September

06 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

27 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

11 May 2023 15:05:01 By Nasdaq GlobeNewswire

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

23 Mar 2023 15:50:08 By Nasdaq GlobeNewswire

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

08 Mar 2023 06:00:02 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

10 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

15 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

09 Nov 2022 15:05:02 By Nasdaq GlobeNewswire

Rezolute to Present at the Jefferies London Healthcare Conference

01 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting

20 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress

15 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Rezolute Announces Presentation at the 60th Annual ESPE Meeting

07 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

01 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

12 May 2022 15:05:01 By Nasdaq GlobeNewswire